News & Comment

Artificial intelligence and neurotechnology promise to transform neurological care, but their acceptance will depend on public trust. Such trust must be earned and maintained through responsible development, transparent reporting, public engagement and ethical oversight. Without these foundations, even highly beneficial technologies may fail to gain legitimacy or uptake.

Aspects of modern society, such as artificial lighting and rigid schedules, create ‘social jetlag’ — a mismatch between biological chronotypes and societal demands. This circadian misalignment particularly affects evening chronotypes, leading to sleep deprivation, mental health issues and physical disorders. Flexible schedules and environmental modifications could restore natural sleep patterns and improve well-being.

Absence of Lewy body pathology in the form of Parkinson disease caused by mutations in the LRRK2 gene does not equate to a lack of α-synuclein pathology, two new studies have shown.

A new phase III trial has shown that the small-molecule CGRP receptor antagonist ubrogepant can alleviate premonitory symptoms in the prodromal phase of migraine.

A new study has identified cerebrospinal fluid proteomic signatures that are linked to frontotemporal lobar degeneration — one of the most common causes of early-onset dementia.

A new study suggests a role for apolipoprotein E in the pathogenesis of Alzheimer disease in people with Down syndrome.

The oral orexin receptor 2-selective agonist oveporexton ameliorates the symptoms of narcolepsy type 1, according to a phase II trial.

A bespoke virtual assistant based on artificial intelligence has outperformed neurologists in the diagnosis of chronic ataxias in a recent study.

New work shows that transplantation of dopaminergic progenitor cells derived from human induced pluripotent stem cells is safe and could be effective in Parkinson disease.

Measures of glymphatic function could serve as markers of Huntington disease and its progression, new research has shown.

Single-molecule analysis of amyloid-β antibody binding has shown that lecanemab preferentially binds to small aggregates that form early in Alzheimer disease.

The Society for Equity Neuroscience (SEQUINS) was founded in 2024 to identify and address global inequities in brain health. Ahead of the inaugural SEQUINS conference in May 2025, we asked Founding President Bruce Ovbiagele about his expectations and aspirations for the conference and for the future of SEQUINS.

A population cohort study has shown that Epstein–Barr virus interacts with genetics to increase the risk of multiple sclerosis.

We spoke with neurologist Esther Bui from Canada about her work to improve neurological health for women.

Walking the Talk for Dementia is no ordinary conference, but an experience that is designed to bring together people with diverse perspectives on dementia, including people with lived experience, and to foster new ways of thinking and collaborating. We asked founder Fernando Aguzzoli-Peres to tell us more about his unique initiative.